Custom Peptide CDMO Services
Next generation GLP-1R & Incretin modulating analogs
Supporting clinical development of next-generation GLP-1 and incretin receptor
agonists and antagonists, through the manufacture of clinical trial material (CTM)
for Phase I–II studies and IND-enabling programs.
Products are not intended for personal use or resale for
direct-to-consumer personal use or administration.
Discovery to Clinical Phase Studies
Research to GMP grade contract manufacturing for continuous peptide support.
CMC IND
Support
Delivered with CoA and CMC package for IND enabling support/stability studies.
Quality &
Reliability
Rigorous QMS and 30+ years serving biopharma, biotech, and academia to deliver quality and reproducibility.
Native Incretins
Native incretin and metabolic peptides can be modified
to develop analogs with enhanced properties.
| Peptide | Receptor Target | Effect |
|---|---|---|
| GLP-1 Glucagon-like peptide-1 |
GLP-1 receptor (GLP-1R) | Physiological satiety signaling |
| GIP Glucose-dependent insulinotropic polypeptide |
GIP receptor (GIPR) | Glucose and energy regulation |
| Amylin | Amylin receptor (CTR/RAMP complex) | Satiety and gastric emptying |
| PYY | Y2 receptor (Y2R) | Appetite suppression |
| Ghrelin | GHSR | Hunger signaling |
| Glucagon | GIP receptor (GIPR) | Glucose and energy regulation |
Why develop next-generation analogs?
Development of next-generation incretin peptides is focused on improving patient adherence and efficacy, through reduction of GI-related adverse effects, and removal of injection burden by offering oral delivery formats.
Current strategies include extending peptide half-life to reduce dosing frequency and enabling multi-pathway targeting (GLP-1 + GIP + amylin + glucagon).
Learn how our custom peptide manufacturing service can support your next project.
Modifications for analog development
Native peptide sequences can be modified through a range of approaches, including amino acid substitution with non-canonical amino acids (ncAAs), specialized building blocks, cyclization and conjugation.
Single or multiple modifications can be incorporated into a sequence at varying positions including the N-terminus, C-terminus or internally based on chemistry and sequence compatibility. Each peptide is assessed for production feasibility prior to price quotation.
